An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ENDRA Life Sciences to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ENDRA Life Sciences (NASDAQ: NDRA) will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15-16, 2022. The management team will conduct one-on-one virtual meetings with investors. Interested participants can reach out to Needham or Yvonne Briggs at LHA for meeting requests. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization, primarily targeting liver conditions like NAFLD and NASH. This technology integrates with existing ultrasound systems worldwide.
Positive
None.
Negative
None.
ANN ARBOR, Mich.--(BUSINESS WIRE)--
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference being held August 15-16, 2022. Management will host one-on-one virtual meetings with investors. To request a meeting, please contact Needham or Yvonne Briggs of LHA at ybriggs@lhai.com.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
What is the purpose of ENDRA Life Sciences' participation in the Needham Conference?
ENDRA Life Sciences is participating in the Needham Virtual Med Tech & Diagnostics 1x1 Conference to engage with investors through one-on-one meetings.
When is the Needham Virtual Med Tech & Diagnostics Conference scheduled?
The conference will be held on August 15-16, 2022.
What technology does ENDRA Life Sciences focus on?
ENDRA Life Sciences focuses on Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which aims to visualize tissue similarly to MRI but at a fraction of the cost.
What conditions does ENDRA's TAEUS® technology target?
TAEUS® primarily targets liver conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
How does ENDRA's technology benefit healthcare?
ENDRA's technology allows for cost-effective imaging at the point of care, enhancing diagnostic capabilities for chronic liver conditions affecting over one billion people globally.
